Wellgen Medical Founder Dr. Eason Lin Delivers Back-to-Back Talks Advocating Early Detection of Metastatic Cancer

A Dual Engagement — Advocating for Early Cancer Detection
Wellgen Medical Founder & CEO Dr. Eason Lin gave back-to-back talks advocating for the early detection of metastatic cancer through NextGen Digital Cytology, engaging both clinical and technology communities in a single week.
At NTUH — Improving Detection Sensitivity for Cytopathologists
Dr. Lin first spoke at the Department of Pathology, National Taiwan University Hospital (NTUH), presenting to a group of cytopathologists on how NextGen Digital Cytology can improve the detection sensitivity of metastatic cancer, directly addressing a critical need in clinical diagnostics.
At the Snapdragon Compute Ecosystem Summit — The Hardware Behind the Innovation
Dr. Lin later attended the 2025 Snapdragon Compute Ecosystem Summit, speaking to a full room of ecosystem partners about Digital Cytology and how Qualcomm's NPU technology helps improve AI inference time and energy performance—bridging the gap between clinical application and hardware innovation.
Industry Value — Innovation Built on Partnership
Wellgen Medical remains committed to innovation, made possible through the continued support of hospital users and ecosystem partners. These engagements reflect the company's ongoing efforts to advance its core mission of "AI-Assisted Diagnosis" across both clinical and technology communities.